News TagCloud
- Agreement
- Auris
- BioValley
- Board
- Drug
- EBIT
- European
- Genzyme
- Half
- Lonza
- Management
- Manufacturing
- Medical
- Novartis
- Novozymes
- Performance
- Phase
- QIAGEN
- Quarter
- RARE
- Results
- Roche
- Round
- Siegfried
- Straumann
- Syna
- Syngenta
- Third
- Unia
- announces
- commercial
- data
- disease
- growth
- holding
- million
- mondoBIOTECH
- named
- patients
- positive
- reporting
- reports
- research
- results
- revenues
- rights
- show
- significantly
- stable
- treatment
BioValley News
Santhera secures commercial rights for the use of Catena® (idebenone) in the treatment of primary progressive Multiple Sclerosis
So far, Santhera, a pharmaceutical company headquartered in Liestal (BL), has been providing idebenone as study medication in a phase II trial, which is assessing the efficacy of ideboneone in the treatment of primary progressive...[more]
Syngenta Board proposes to elect two new directors at AGM
Basel, Switzerland February 6, 2013 - Syngenta announced today that the Board will propose the election of two new directors, Eleni Gabre-Madhin and Eveline Saupper, at the Annual General Meeting on April 23, 2013. In addition to...[more]
Syngenta - 2012 Full Year Results
Mike Mack, Chief Executive Officer, said:“In 2012, crop prices rose sharply as adverse weather conditions in several regions resulted in significant production shortfalls, once again highlighting the fragility of global...[more]
apceth Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic as Part of the m4 Initiative of the Munich Biotech Cluster
Development of apceth’s first innovative “Advanced Therapy Medicinal Product” based on modified adult stem cells for cancer therapyapceth as participant in the “m4 Personalized Medicine and Targeted Therapies” initiative of the...[more]
Lonza to Adpapt its Management Structure to Focus on Target Markets and Improve Profitability
Basel, Switzerland, 4 February 2013 – Lonza today announced its plans to adapt the management structure of the company to focus on its target markets and to improve the effectiveness of its worldwide organizational structure and...[more]
Lonza Joins Roundtable on Sustainable Palm Oil
Basel, Switzerland, 30 January 2013 – Lonza today announced membership in the Roundtable on Sustainable Palm Oil (RSPO), an international organization of growers, processors, traders, non-governmental organizations, investors,...[more]
mondobiotech holding AG (SIX:RARE) announces the exercise of the convertion rights by BioPharma Invest AG
Stans, Switzerland – 25 January 2013 – mondoBIOTECH holding AG(“mondoBIOTECH”), a Swiss–based drug discovery company focused on repurposing drugs in rare and neglected diseases and listed on the SIX Swiss Exchange (SIX: RARE),...[more]
Lophius Biosciences Closes Financing Round and Expands Management Board
Financing round closed with volume of about 4 Mio. EUR VRD GmbH and WIC GmbH become new investors Prof. Dr. Ralf Wagner appointed as Managing Director ...[more]
Novozymes reports EBIT growth of 17%, exceeding outlook
COPENHAGEN, DENMARK – January 21, 2013 - Novozymes, the world leader in bioinnovation and industrial enzymes, today reported 7% sales growth in 2012 compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net...[more]
Syngenta e-licensing heralds new era for sharing of plant science innovation
Basel, Switzerland January 17, 2013 Easy, internet-based access to key patented technologiesFair, reasonable and transparent terms for allFree use for academic and non-profit organizations Syngenta today launched a landmark...[more]
News Categories
News Archive
Contact Form
Leonhard E. Loew
BioValley Basel Association
Aeschenvorstadt 57
CH-4051 Basel / Switzerland
Tel. +41 61 271 59 30
info(at)biovalley.ch
